[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Clinical Evidence Synopsis
May 10, 2016

Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

Author Affiliations
  • 1Psychiatric Research Unit, Child and Adolescent Psychiatric Department, Region Zealand Psychiatry, Region Zealand, Denmark
  • 2Psychiatric Research Unit, Region Zealand Psychiatry, Region Zealand, Denmark
  • 3Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
JAMA. 2016;315(18):2009-2010. doi:10.1001/jama.2016.3611
Abstract

Clinical Question  Is treatment with methylphenidate associated with benefits or harms for children and adolescents with attention-deficit/hyperactivity disorder (ADHD)?

Bottom Line  Methylphenidate is associated with improvement in ADHD symptoms, general behavior, and quality of life; however, due to the very low quality of the evidence, the magnitude of the associated improvement is uncertain. Methylphenidate was associated with an increased risk of nonserious adverse events. There are too few data to assess the association with serious adverse events.

×